Beijing Bohui Innovation Biotechnology Group Co., Ltd.
博晖创新
300318
Shenzhen Stock Exchange
Company Profile
After years of development and accumulation, the company has gradually established unique core competencies in strategic positioning, technological innovation, corporate culture, quality management, and talent development. (I) Adherence to a Corporate Strategy Focused on the Health Industry For over two decades since its establishment, the company has upheld its mission of "Innovating Life Sciences for Human Health." Centered on the healthcare industry, it prioritizes technological innovation as the foundation for organic growth while pursuing strategic expansions. Today, it has evolved into a high-tech enterprise in the life sciences sector, integrating R&D, production, sales, and after-sales services, with dual core businesses in diagnostic testing and biopharmaceuticals. (II) Commitment to Technological Innovation Technological innovation serves as the cornerstone of the company’s development. Through sustained R&D investment, close monitoring of industry trends and cutting-edge technologies, and active industry collaboration, the company has strengthened its independent innovation capabilities. This has enabled it to build robust technical development and scientific research advantages, ensuring sustained product competitiveness. The company and its key subsidiaries are all recognized as National High-Tech Enterprises. Additionally, the company has undertaken multiple national-level projects, including the National High-Tech Research and Development Program (863 Program) and the National Major Scientific Instrument Development Projects during the 12th and 13th Five-Year Plan periods. (III) Cultivation of a Pragmatic Corporate Culture The company places strong emphasis on corporate culture, adhering to a people-oriented philosophy and scientific management principles to guide daily operations. Under this culture, management personnel lead by example, fostering a results-driven work environment to ensure effective implementation of initiatives. In plasma station expansion, the company leverages regional advantages and collaborates with government authorities to increase coverage in suitable areas. As of the reporting period, it operates 19 plasma collection stations, with 4 additional stations awaiting approvals or inspections. For major projects, the company overcame challenges to advance the relocation of Hebei Bohui’s production base to Qujing, Yunnan, and the resumption of operations at Langfang Bohui, achieving phased progress. (IV) Implementation of Rigorous Quality Management Systems The company prioritizes quality system development, having obtained certifications for Medical Device GMP, ISO13485, and ISO9001. Through continuous improvement and effective execution of these systems, it ensures scientific control over R&D processes, production, and product quality. This guarantees a stable supply of high-quality products to meet diverse customer needs and enhance user experience. Subsidiaries are required to strictly comply with industry regulations and standards in plasma collection, maintain GMP-compliant production facilities, and uphold stringent quality controls. These efforts collectively elevate overall quality standards, prevent incidents, and ensure drug safety. (V) Focus on Talent Development To support long-term growth, the company emphasizes the parallel development of technical expertise and managerial capabilities. It refines talent cultivation mechanisms and succession plans through a hybrid model of internal training and high-end talent recruitment, building a multi-tiered talent pipeline. Key professional teams are strengthened across departments to meet diversified business needs. By optimizing promotion pathways, enhancing employee benefits, and providing tailored training programs—including onboarding, technical upskilling, and leadership development—the company boosts staff cohesion and secures talent resources for its rapid growth strategy.
Full description
The company's business involves two sub areas: inspection and testing, and biological products. The company's inspection and testing business products consist of two parts: inspection instruments and testing reagents, with a customer base covering both medical and non medical institutions. The company's products for medical institutions mainly involve in the field of in vitro diagnostic testing, including human trace element testing and human papillomavirus (HPV) testing; The company provides testing equipment for non medical institutions, mainly small mass spectrometry analyzers and related products. The main users are environmental protection testing institutions and laboratories of scientific research institutions such as biology and chemistry. The human trace element detection system produced by the company is an independent and closed detection system composed of detection instruments and reagents. It has been on the market for many years and has a wide and stable user base. The detection instruments have been installed and used in many hospitals, and the sales revenue of reagents accounts for a relatively high proportion in this product system. It is one of the important sources of the company's inspection and testing revenue. The company's HPV detection system consists of two parts: instrument and HPV reagent kit (microfluidic chip+reagent), and is also an independent closed detection system. This system relies on microfluidic technology to achieve complete automation of nucleic acid molecule detection, making it the first fully automated nucleic acid molecule detection product in China. HPV products are currently an important source of revenue for the company's inspection and testing business. In the medical field, the company's products are mainly sold based on testing instruments, with reagents as supporting products and instrument combinations. The instruments and reagents together form an independent and closed testing system. The company mainly adopts instruments to occupy the market, build a customer network, and drive reagent sales through technical services; A business strategy that consolidates and enhances the market position with its own innovative technology, thereby continuously improving the company's ability to sustain operations. The sales terminals of the company's medical testing products are hospitals, third-party testing institutions, etc. Product sales are mainly carried out through distribution. The company has established long-term and stable partnerships with multiple distributors across the country, with each distributor selling the company's products and providing product services in the agreed areas or medical institutions. The company has great autonomy in selecting distributors and does not rely on a specific distributor. The sales terminals of the company's non medical testing products include environmental testing institutions and laboratories of scientific research institutions such as biology and chemistry. Product sales are conducted through direct sales and dealer sales. Hebei Bohui and Guangdong Weilun, under the company's subsidiaries, are mainly engaged in the research and development, production, and sales of blood products. Their product range covers multiple varieties of human blood albumin, human immunoglobulin, and human coagulation factor, basically covering important varieties of blood products. The sales model of the company's blood products includes distribution and direct sales. The distribution is a buyout sales model, with the main customer group being pharmaceutical distribution enterprises, and the main customer group of the direct sales model including hospitals and chain pharmacies.